CVS chooses Amgen's new cholesterol drug over competitor

NEW YORK, Nov 23 (Reuters) - U.S. drug benefit manager CVS Health said on Monday that it would add Amgen Inc.'s Repatha cholesterol treatment to its list of covered drugs for private plans over a competing treatment from Sanofi SA and Regeneron Pharmaceuticals.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.